Optimizing Care in HER2+ Breast Cancer: Integrating Fertility Preservation and Advanced Treatment Approaches - Episode 2
Treatment Planning for HER2+ Breast Cancer: The Role of Ovarian Function Suppression
Panelists discuss how ovarian suppression combined with endocrine therapy shows benefits for premenopausal patients with triple-positive breast cancer, particularly in younger, high-risk populations.
Video Player is loading.
Video content above is prompted by the following:
Fertility Preservation and Ovarian Suppression
Key Themes:
- Ovarian suppression recommendations
- Based on SOFT/TEXT trial data, showing benefit for high-risk premenopausal patients
- Particularly beneficial for patients under 35 years of age
- Recommended for patients receiving chemotherapy or considered high risk
- HER2-positive patients may benefit from ovarian suppression
- HERA trial analysis
- Recent analysis presented at ESMO 2024 examined premenopausal women with triple-positive breast cancer
- Found survival outcomes of ovarian function suppression plus aromatase inhibitor superior to ovarian function suppression plus tamoxifen
- Ovarian function suppression combined with endocrine therapy was superior to tamoxifen alone
Notable Insights:
- Dr Vidal shared: “For my premenopausal hormone receptor–positive patients for whom I think there’s high risk, those patients, I definitely add ovarian suppression.”
- Dr McCann emphasized: “I always tell my patients that my favorite medication for them is the one they’re willing to take.”
Related Content:
